ArticleInternational journal of molecular sciences2020
Affinity Capture Enrichment versus Affinity Depletion: A Comparison of Strategies for Increasing Coverage of Low-Abundant Human Plasma Proteins.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Systematic Evaluation of Depletion and Enrichment Technologies for Platelet-Free Plasma Proteomics.Journal of proteome research · 2026Article
- Plasma proteomic signatures associated with abdominal aortic aneurysm presence, growth, and risk of mortality.Scientific reports · 2026Article
- Affinity-Enriched Plasma Proteomics for Biomarker Discovery in Abdominal Aortic Aneurysms.Proteomes · 2024Article
- Small molecule modulation of protein corona for deep plasma proteome profiling.Nature communications · 2024Article
- Deep Plasma Proteome Profiling by Modulating Single Nanoparticle Protein Corona with Small Molecules.bioRxiv : the preprint server for biology · 2024Article
- Deep Plasma Proteomics with Data-Independent Acquisition: Clinical Study Protocol Optimization with a COVID-19 Cohort.Journal of proteome research · 2024Article
- Plasma proteomics and lipidomics facilitate elucidation of the link between Alzheimer's disease development and vessel wall fragility.Scientific reports · 2024Article
- A Carrier-Based Quantitative Proteomics Method Applied to Biomarker Discovery in Pericardial Fluid.Molecular & cellular proteomics : MCP · 2024Article
- Promises and Challenges of populational Proteomics in Health and Disease.Molecular & cellular proteomics : MCP · 2024Article
- Serum/Plasma Proteome in Non-Malignant Liver Disease.International journal of molecular sciences · 2024Review
- Circulating Proteins as Diagnostic Markers in Gastric Cancer.International journal of molecular sciences · 2023Review
- Novel therapeutic strategies for injured endometrium: intrauterine transplantation of menstrual blood‑derived cells from infertile patients.Stem cell research & therapy · 2023Article
- Low-Abundance Protein Enrichment for Medical Applications: The Involvement of Combinatorial Peptide Library Technique.International journal of molecular sciences · 2023Review
- Proteomic Analyses of Autologous Chondrocyte Implantation Plasma Highlight Cartilage Acidic Protein 1 as a Candidate for Preclinical Screening.The American journal of sports medicine · 2023Article
- Article
- Clinical Proteomics: Liquid Chromatography-Mass Spectrometry (LC-MS) Purification Systems.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma.International journal of molecular sciences · 2022Article
- Recent Developments in Clinical Plasma Proteomics-Applied to Cardiovascular Research.Biomedicines · 2022Review
- Comprehensive Plasma N-Glycoproteome Profiling Based on EThcD-sceHCD-MS/MS.Frontiers in chemistry · 2022Article
- Determining Plasma Protein Variation Parameters as a Prerequisite for Biomarker Studies-A TMT-Based LC-MSMS Proteome Investigation.Proteomes · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we evaluated four small molecule affinity-based probes based on agarose-immobilized benzamidine (ABA), O-Phospho-L-Tyrosine (pTYR), 8-Amino-hexyl-cAMP (cAMP), or 8-Amino-hexyl-ATP (ATP) for their ability to remove high-abundant proteins such as serum albumin from plasma samples thereby enabling the detection of medium-to-low abundant proteins in plasma samples by mass spectrometry-based proteomics. We compared their performance with the most commonly used immunodepletion method, the Multi Affinity Removal System Human 14 (MARS14) targeting the top 14 most abundant plasma proteins and also the ProteoMiner protein equalization method by label-free quantitative liquid chromatography tandem mass spectrometry (LC-MSMS) analysis. The affinity-based probes demonstrated a high reproducibility for low-abundant plasma proteins, down to picomol per mL levels, compared to the Multi Affinity Removal System (MARS) 14 and the Proteominer methods, and also demonstrated superior removal of the majority of the high-abundant plasma proteins. The ABA-based affinity probe and the Proteominer protein equalization method performed better compared to all other methods in terms of the number of analyzed proteins. All the tested methods were highly reproducible for both high-abundant plasma proteins and low-abundant proteins as measured by correlation analyses of six replicate experiments. In conclusion, our results demonstrated that small-molecule based affinity-based probes are excellent alternatives to the commonly used immune-depletion methods for proteomic biomarker discovery studies in plasma. Data are available via ProteomeXchange with identifier PXD020727.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.